Results 51 to 60 of about 250,918 (350)

Recent Advances in Liver Cancer Stem Cells: Non-coding RNAs, Oncogenes and Oncoproteins

open access: yesFrontiers in Cell and Developmental Biology, 2020
Hepatocellular carcinoma (HCC) is one of the most prevalent malignancies worldwide, with high morbidity, relapse, metastasis and mortality rates. Although liver surgical resection, transplantation, chemotherapy, radiotherapy and some molecular targeted ...
Juan Li, Ying Zhu, Ying Zhu
doaj   +1 more source

Selenite Downregulates STAT3 Expression and Provokes Lymphocytosis in the Liver of Chronically Exposed Syrian Golden Hamsters

open access: yesMolecules, 2021
Arsenic is considered a worldwide pollutant that can be present in drinking water. Arsenic exposure is associated with various diseases, including cancer.
María Elena Camacho-Moll   +9 more
doaj   +1 more source

Comparative study of the evolution of human cancer gene duplications across fish [PDF]

open access: yesarXiv, 2021
Comparative studies of cancer-related genes allow us to gain novel information about the evolution and function of these genes, but also to understand cancer as a driving force in biological systems and species life histories. So far, comparative studies of cancer genes have focused on mammals.
arxiv  

Recent Progress of Targeted G-Quadruplex-Preferred Ligands Toward Cancer Therapy

open access: yesMolecules, 2019
A G-quadruplex (G4) is a well-known nucleic acid secondary structure comprising guanine-rich sequences, and has profound implications for various pharmacological and biological events, including cancers.
Sefan Asamitsu   +4 more
doaj   +1 more source

Gastrointestinal Tumors: Phytochemical and Drug Combinations Targeting the Hallmarks of Cancer

open access: yesApplied Sciences, 2021
Cancer is a worldwide burden resulting in millions of deaths each year. In particular, gastrointestinal tumors are life-threatening malignancies and one of the leading reasons for death in developed countries.
Emanuele Salvatore Scarpa   +2 more
doaj   +1 more source

Post‐operative mortality and recurrence patterns in pancreatic cancer according to KRAS mutation and CDKN2A, p53, and SMAD4 expression

open access: yesThe Journal of Pathology: Clinical Research, 2023
Alterations in KRAS, CDKN2A (p16), TP53, and SMAD4 genes have been major drivers of pancreatic carcinogenesis. The clinical course of patients with pancreatic cancer in relation to these driver alterations has not been fully characterised in large ...
Yohei Masugi   +24 more
doaj   +1 more source

Deregulated Metabolic Pathways in Ovarian Cancer: Cause and Consequence

open access: yesMetabolites, 2023
Ovarian cancers are tumors that originate from the different cells of the ovary and account for almost 4% of all the cancers in women globally. More than 30 types of tumors have been identified based on the cellular origins.
Roopak Murali   +7 more
doaj   +1 more source

Evidence that synthetic lethality underlies the mutual exclusivity of oncogenic KRAS and EGFR mutations in lung adenocarcinoma

open access: yeseLife, 2015
Human lung adenocarcinomas (LUAD) contain mutations in EGFR in ∼15% of cases and in KRAS in ∼30%, yet no individual adenocarcinoma appears to carry activating mutations in both genes, a finding we have confirmed by re-analysis of data from over 600 LUAD.
Arun M Unni   +4 more
doaj   +1 more source

Multiple Roles of the RUNX Gene Family in Hepatocellular Carcinoma and Their Potential Clinical Implications

open access: yesCells, 2023
Hepatocellular carcinoma (HCC) is one of the most frequent cancers in humans, characterised by a high resistance to conventional chemotherapy, late diagnosis, and a high mortality rate.
Milena Krajnović   +3 more
doaj   +1 more source

Brief inactivation of c-Myc is not sufficient for sustained regression of c-Myc-induced tumours of pancreatic islets and skin epidermis [PDF]

open access: yes, 2004
Background Tumour regression observed in many conditional mouse models following oncogene inactivation provides the impetus to develop, and a platform to preclinically evaluate, novel therapeutics to inactivate specific oncogenes.
Abouna, Sylvie   +5 more
core   +2 more sources

Home - About - Disclaimer - Privacy